About ITB


Over the last 22 years, ITB has successfully developed & incubated investments in high technology, building a portfolio of over RM1 billion ringgit during this period. Its current holdings include those of

  • DGSB, an ACE-listed telco and media equipment, and ERP services company
  • Sengenics – a functional proteomics group (biotech)

ITB’s portfolio companies collectively employ some 7,000 staff at locations in Malaysia, Philippines, China, Thailand, Indonesia, Singapore and the UK. The expertise in the ITB group include those of advanced semiconductor assembly of RF, Optoelectronics and Sensors; Biotech diagnostics; Systems Integration in Telco, Media, Self-Service Kiosks, with skillsets in Payments, Augmented Reality, Games Production and Data Analytics .

ITB’s core activity is investment in high growth technology companies in three broad technology sectors namely electronics manufacturing services (“EMS”), financial transaction processing (“Fintech’) & Media and bio-technology. The major portfolio companies in the respective tech sectors are Inari Amertron Berhad (“Inari”), Numoni Pte. Ltd. (“Numoni’) and Sengenics Corporation Pte. Ltd (“Sengenics”). Inari is involved in the Outsourced Semiconductor Assembly and Test (“OSAT”) industry for RF products and tailored EMS contract manufacturing to the semiconductor optoelectronic industry. As at 30 June 2018, Inari operates 12 plants situated in Malaysia, Philippines and China with total production floor space of over 1 million square feet. In FY 2018, Inari reported revenue of RM1,376 million, a 17% increase as compared to RM1,177 million in FY 2017, and its earnings improved from RM229 million in FY 2017 to RM260 million in FY 2018.